The management of suboptimal ovarian responders remains a challenging task in IVF. These patients are frequently managed with an intense stimulation protocol of ovarian stimulation in order obtain the maximum number of embryos and, therefore, maximize the cumulative live birth rate. However, the concept of "the more the better" has been recently defied by the one of "mild stimulation". Defenders of this protocol state that with mild stimulation only the best quality oocytes are allowed to grow and, therefore, higher quality embryos will be obtained. However, the impact of the intensity of ovarian stimulation on embryo quality is far from consensual. Moreover, its effect on early embryo development has never been evaluated.
Therefore, the investigators set out to perform this randomized controlled trial comparing the number of GQB and the morphokinetic parameters of early embryo development in infertile patients undergoing two different intensities of ovarian stimulation, a milder approach (CC plus 150 IU daily dose of rFSH) and a more intense approach (300 IU daily dose of rFSH).

开始日期2021-11-23

申办/合作机构-

NCT02809989 / CompletedN/A

Multicentre, Prospective, Open, Non-interventional Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen in the Clinical Routine of the IVF- / ICSI-treatment.

The aim of this non-interventional study is to extend the knowledge on effectiveness of Ovaleap® (number of oocytes and pregnancy rate) during routine IVF- or ICSI-treatment using a Gonadotropin-releasing hormone (GnRH) antagonist protocol in a large number of patients.

开始日期2016-03-31

申办/合作机构

Teva Pharma

EUCTR2009-017674-20-BE / Not yet recruitingN/A

Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoingassisted reproductive technologies.A multi-national, multi-centre, randomised, controlled, assessor-blind, parallel groupPhase III study including follow-up periods

开始日期2010-04-30

申办/合作机构

BioGeneriX AG

100 项与重组促卵泡激素α生物类似药(Teva Pharmaceutical Industries Ltd.) 相关的临床结果

登录后查看更多信息

100 项与重组促卵泡激素α生物类似药(Teva Pharmaceutical Industries Ltd.) 相关的转化医学

登录后查看更多信息

100 项与重组促卵泡激素α生物类似药(Teva Pharmaceutical Industries Ltd.) 相关的专利（医药）

登录后查看更多信息

项与重组促卵泡激素α生物类似药(Teva Pharmaceutical Industries Ltd.) 相关的文献（医药）

2022-08-01·DRUG DISCOVERY TODAY2区 · 医学

Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?

2区 · 医学

Article

作者: de Mora, Fernando ; Howles, Colin M

Unfounded skepticism relating to biosimilars, arising from the assertion that they are not molecularly identical to their original counterpart, fails to acknowledge that no biological medicine, including Gonal-f® (from Merck Serono) is identical to itself. Molecular differences between the biosimilar and the reference medicines are irrelevant and clinically undetectable as long as they are contained within the accepted variability for the original medicine. Accordingly, the minor differences in 'ongoing pregnancy rate' and 'live birth' rate reported in a recent meta-analysis of biosimilars of Gonal-f® from Chua et al. are probably driven by product-unrelated factors, notwithstanding the fact that of the four products under analysis, only Ovaleap® (from Theramex UK Ltd) and Bemfola® (from Gedeon Richter Plc) can unambiguously be considered to be biosimilars. The EU Biosimilars model has proven successful, but some healthcare professionals, building on highly arguable premises, voice a distrust in biosimilars. Only if such scientifically unfounded distrust is reverted, the full promise of rFSH alfa biosimilars for reproductive medicine patients is likely to be fulfilled.

2021-10-01·Reproductive biomedicine online3区 · 医学

Follitropin alpha versus beta in a first GnRH antagonist ICSI cycle: a retrospective cohort study

3区 · 医学

Article

作者: Blockeel, Christophe ; Tournaye, Herman ; De Vos, Michel ; Verheyen, Greta ; Drakopoulos, Panagiotis ; Van den Haute, Lien

RESEARCH QUESTION:

Are cumulative live birth rates (CLBR) after follitropin alpha (Ovaleap®) and follitropin beta (Puregon®) similar when used for ovarian stimulation with ICSI (intracytoplasmic sperm injection) in a first-rank gonadotrophin-releasing hormone (GnRH) antagonist protocol?

DESIGN:

Retrospective single-centre cohort study including 832 infertile patients undergoing ovarian stimulation with a daily dose of 150-225 IU FSH in their first ICSI cycle at a tertiary referral centre between July 2016 and July 2019. Of those, 349 patients used Ovaleap and 483 patients received Puregon.

RESULTS:

Baseline characteristics were not statistically different between the groups. The duration of stimulation was slightly longer in the Ovaleap group (10.6 ± 1.7 versus 10.3 ± 1.6 days; P = 0.012). The number of mature oocytes was not statistically different and there was no significant difference in fertilization rate or embryo utilization rate between the two groups. After fresh embryo transfer, biochemical pregnancy rate (137/349 [39.3%] versus 186/483 [38.5%]) as well as clinical pregnancy rate (105/349 [30.1%] versus 152/483 [31.5%]) were comparable (P = 0.83 and 0.67, respectively). Live birth rate (LBR) after fresh embryo transfer (94/349 [26.9%] versus 141/483 [29.2%]; P = 0.48) and CLBR (199/349 [57.0%] versus 287/483 [59.4%]; P = 0.49) were not significantly different. Multivariable regression analysis revealed that the type of gonadotrophin was not associated with CLBR (P = 0.28).

CONCLUSION:

This retrospective study shows no significant difference in CLBR between Ovaleap and Puregon in patients undergoing their first GnRH antagonist ICSI cycle.

2021-07-04·Expert review of pharmacoeconomics & outcomes research4区 · 医学

The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature

4区 · 医学

Review

作者: Dumančić, Stipe ; Laganà, Antonio Simone ; Mikuš, Mislav ; Šprem Goldštajn, Marina ; Andrisani, Alessandra ; Ćorić, Mario ; Orešković, Slavko ; Buzzaccarini, Giovanni ; Noventa, Marco

Introduction: To study the impact of biosimilars in assisted reproductive treatments, we performed a review of the literature. Biosimilars are a bioequivalent chemical drug referred to the original. Their production is strongly requested in order to reduce drug cost and reduce health economic impact on national health system. In assisted reproductive treatments different gonadotropin biosimilars are being produced.Areas covered: For this reason, we performed a review of the literature on follitropin alfa Gonal-F biosimilar, Ovaleap and Bemfola, to assess their cost efficacy in national health system. Cost effective (CE) analysis and incremental cost-effectiveness ratio (ICER) were used as parameters for biosimilar impact evaluation in the national health system economy. In particular, they had only slight impact on cost reduction of recombinant follitropin alfa products in Europe.Expert opinion: considering cost-effective analysis, Gonal-F remains the first choice for national health systems. However, well-designed powered methods are strongly needed to assess biosimilars cost-effectiveness.

项与重组促卵泡激素α生物类似药(Teva Pharmaceutical Industries Ltd.) 相关的新闻（医药）

2021-04-13

·GlobeNewswire

New York, April 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Top 50 Biosimilar Drug Manufacturers 2021" - PLUS Regional Market Analysis AND COVID-19 Recovery ScenariosTop 50 Biosimilar Companies Report– Read on to determine how you can exploit the impending business opportunities emerging in this sector along with profile of top 50 companies operating in the market. The company profiles are divided into three segments including: • Major Players: Profiles of major 15 companies that account for over 60% market share in the global biosimilars market • Mid-Range Players: Profiles of 20 pioneering companies that account for significant market share and focuses on the innovative strategic collaborations and M&A • Ones to Watch – New Players: Profiles of 15 growing companies that are investing a huge amount of money in biosimilars R&D and focuses on new drug development The global biosimilars market is projected to reach at a market value of USxx billion by 2023 with a lucrative CAGR during the forecast period. This report shows you the potential revenues streams to 2023, assessing the top 20 products, the major 50 key players, qualitative analysis, opportunities trends, and business prospects in the biosimilars industry. How this report will benefit you This new study is envisioned for anyone requiring commercial in-depth analyses for the global biosimilars market along with detailed company profiles of top 50 companies operating in the market. Our new study assists you to evaluate the overall global and regional market for biosimilars. Get the financial analysis of the overall market and major 50 player’s revenue predictions till 2023. High opportunity remains in this fast-growing Biosimilars Market. See how to exploit the existing opportunities in the market to gain maximum advantage in the near future. Forecasts to 2023 and other analyses reveal the commercial prospects • In addition to profiles of top 50 biosimilar companies, our new study provides you with revenue forecasting to 2023 • Includes growth rates for each segment and regional markets along with COVID-19 impact analysis • The profiles of the top 50 companies – descriptive and comprehensive data including company snapshot, overview, commercial developments, company shares & ranking, and detailed financial analysis with revenue and segment revenue forecast till 2023. • COVID-19 set to have a positive impact on the biosimilars industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry. Discover sales forecasts for the global and regional market forecasts from 2020-2023 Along with revenue prediction for the overall global market, there is segmentations by product for 20 major biosimilar drugs and 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA. Global market revenue and growth forecasts from 2020 to 2023 by product The global biosimilars market revenue will surpass $16.57 billion in 2020 with a lucrative CAGR during the forecast period 2021-2023 to reach significant revenue growth to 2023. The major product considered in the report are: • Adalimumab • Etanercept • Trastuzumab • Infliximab • Insulin Glargine • Rituximab • Pegfilgrastim • Epoetin Alfa • Teriparatide • Bevacizumab • Insulin Lispro • Darbepoetin Alfa • Filgrastim • Enoxaparin • Eculizumab • Natalizumab • Cetuximab • Follitropin Alfa • Somatropin • Dornase Alfa • Other Biosimilars Regional market revenue and growth forecasts from 2020 to 2023: • North America • Europe • Asia Pacific • Latin America • Middle East and Africa Leading companies and those seeking to enter the market The report includes profiles of 50 major companies involved in the Biosimilar Market. The companies profiled in this report include: Amgen Inc.; Novartis AG; Merck & Co., Inc.; Pfizer Inc.; Eli Lilly and Company; Biogen Inc.; Teva Pharmaceutical Industries Ld.; Celltrion Healthcare Co., Ltd.; Sanofi; Samsung Bioepis; Mylan N.V.; Fresenius Kabi AG; Intas Pharmaceuticals Ltd.; AbbVie Inc.; STADA Arzneimittel AG ; Coherus; Dr Reddy’s Laboratories Ltd.; Boehringer Ingelheim International GmbH; Daiichi Sankyo Co Ltd.; Biocon Ltd.; Nichi-Iko; Fujifilm Kyowa Kirin Biologics; Zydus Cadila; Apotex Inc.; Lupin Ltd.; PolPharma; Zhejiang Hisun Pharma; Cipla Ltd.; Generium; Torrent Pharma; Shenzhen Techdow Pharmaceutical; Mochida; Gedeon Richter Plc.; Aurobindo Pharma; USV Biologics; Egis Pharmaceuticals Plc.; Hetero; Ligand Pharmaceuticals; Xbrane Biopharma AB; Alvotech; Mabion S.A.; Reliance Life Sciences; Harvest Moon Pharmaceuticals; AryoGen; Jiangsu Simcere Pharmaceutical; Mundipharma International Ltd.; Kashiv Biosciences; Gene Techno Science; Avesthagen Pharma AG; Formycon AG. Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. In summary, our 372-page report delivers you with the following knowledge: • Revenue forecasts from 2020 to 2023 for the global biosimilars market and subsegments (by products and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation • Detailed profiles of Top 50 Biosimilar Companies, with financial forecasts for net revenues, operating income, R&D investment, and biosimilar segment revenue • Revenue forecasts from 2020 to 2023 for 5 regional markets – See forecasts for the biosimilars market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. This study is for everybody needing commercial analyses for the Global Biosimilars market and Detailed Analysis of 50 Leading Companies. You will get the most recent data, opportunities, trends, and predictions. The Top 50 Biosimilar Companies Report Forecast 2020-2023 will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional market or to understand strategic analysis of leading 50 companies of the biosimilars industry.Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________

生物类似药合作

100 项与重组促卵泡激素α生物类似药(Teva Pharmaceutical Industries Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03GA05	DB00066

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
卵巢过度刺激综合征	澳大利亚	Theramex Australia Pty Ltd	2021-03-10
无排卵	欧盟	Theramex Ireland Ltd.	2013-09-27
无排卵	冰岛	Theramex Ireland Ltd.	2013-09-27
无排卵	列支敦士登	Theramex Ireland Ltd.	2013-09-27
无排卵	挪威	Theramex Ireland Ltd.	2013-09-27
精子发生停滞	欧盟	Theramex Ireland Ltd.	2013-09-27
精子发生停滞	冰岛	Theramex Ireland Ltd.	2013-09-27
精子发生停滞	列支敦士登	Theramex Ireland Ltd.	2013-09-27
精子发生停滞	挪威	Theramex Ireland Ltd.	2013-09-27
多囊卵巢综合征	欧盟	Theramex Ireland Ltd.	2013-09-27
多囊卵巢综合征	冰岛	Theramex Ireland Ltd.	2013-09-27
多囊卵巢综合征	列支敦士登	Theramex Ireland Ltd.	2013-09-27
多囊卵巢综合征	挪威	Theramex Ireland Ltd.	2013-09-27